- Fund Type: SICAV
- Objective: Growth
- Asset Class: Equity
- Geographic Focus: Spain
Abside Capital SICAV SA
+ Add to WatchlistS3303:SM
6.56 EUR 0.000.00%As of 10:00:32 ET on 05/17/2013.
Snapshot for Abside Capital SICAV SA (S3303)
| Year To Date: | -1.07% | 3-Month: | +0.82% | 3-Year: | -6.53% | 52-Week Range: | 6.26 - 6.86 |
|---|---|---|---|---|---|---|---|
| 1-Month: | -0.24% | 1-Year: | +3.61% | 5-Year: | -7.95% | Beta vs IBEX: | 0.46 |
Fund Profile & Information for S3303
Abside Capital SICAV SA is an open-end investment company incorporated in Spain. The investment company's objective is capital growth. It primarily invests in equity securities.
| Inception Date: | 08-29-2007 | Telephone: | 3491-432-3910 |
|---|---|---|---|
| Managers: | - | ||
| Web Site: | www.nordkapp.es | ||
Fundamentals for S3303
| NAV | (on 2013-05-17) 6.56 |
|---|---|
| Assets (M) | (on 2013-04-04) 2.40 |
| Fund Leveraged | N |
| Minimum Investment | - |
| Minimum Subsequent Investment | - |
Dividends for S3303
No dividends reported
Fees & Expenses for S3303
| Front Load | - |
|---|---|
| Back Load | - |
| Current Mgmt Fee | - |
| Redemption Fee | - |
| 12b1 Fee | - |
| Expense Ratio | - |
Top Fund Holdings for S3303
Filing Date: 07/31/2012| Name | Position | Value | % of Total |
|---|---|---|---|
| SPGB 4.1 07/30/18 | 214 | 192,000 | 12.185% |
| Mylan Inc/PA | 3,200 | 59,896 | 3.801% |
| Amazon.com Inc | 220 | 41,715 | 2.647% |
| Verizon Communications Inc | 1,100 | 40,356 | 2.561% |
| Sanofi | 600 | 39,882 | 2.531% |
| iShares FTSE China 25 Index Fu | 1,400 | 38,926 | 2.470% |
| Yahoo! Inc | 3,000 | 38,622 | 2.451% |
| Alexion Pharmaceuticals Inc | 400 | 34,086 | 2.163% |
| Deutsche Post AG | 2,300 | 33,672 | 2.137% |
| Metro AG | 1,500 | 33,608 | 2.133% |
Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
- 1
- 2
- 3
- 4
- 5
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page